• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.

作者信息

Van den Bogaert W, van der Schueren E, Horiot J C, De Vilhena M, Schraub S, Svoboda V, Arcangeli G, de Pauw M, Van Glabbeke M

机构信息

Radiotherapy Department, University Hospital, Gasthuisberg, Leuven, Belgium.

出版信息

Radiother Oncol. 1995 May;35(2):91-9. doi: 10.1016/0167-8140(95)01538-r.

DOI:10.1016/0167-8140(95)01538-r
PMID:7569030
Abstract

From 1981 to 1984, a randomized study was done by the EORTC Radiotherapy Group comparing a fractionation schedule with three fractions per day (multiple fractions per day, MFD), with or without misonidazole, to conventional fractionation. The aim of the study was to obtain improved local and regional control and survival by shortening of the treatment time in the first 2 weeks of irradiation. Three fractions of 1.6 Gy/day (4-h interval) were given during 10 irradiation days to a total of 48 Gy. After 3-4-weeks interval, a boost was given to 67.2 or 72 Gy also in three fractions per day. This schedule was compared to an identical arm with misonidazole 1 g/m2/day and a third arm with conventional fractionation (70 Gy in 35 fractions, 7 weeks or 75 Gy in 44 fractions, 9 weeks). A total number of 523 patients was included in the study. Acute mucositis was much heavier in patients treated with three fractions per day (Van den Bogaert et al. Int. J. Radiat. Oncol. Biol. Phys. 8: 1649-1655, 1982). Early results, communicated in 1986 (Van den Bogaert et al. Int. J. Radiat. Oncol. Biol. Phys. 12: 587-591, 1986) showed no differences in treatment outcome between the three treatment arms. Long-term results and data on late effects are now available. Survival at 5 years was 18% (SE 1.9%) and locoregional control was 27% (SE 2.9%). No statistically significant differences could be observed between the three treatment arms.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
Radiother Oncol. 1995 May;35(2):91-9. doi: 10.1016/0167-8140(95)01538-r.
2
Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.顺铂与放疗同步进行传统及改良分割方案治疗局部晚期头颈癌:一项欧洲癌症研究与治疗组织(EORTC)的随机II期试验
Eur J Cancer. 2002 Mar;38(5):667-73. doi: 10.1016/s0959-8049(01)00425-7.
3
Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
Radiother Oncol. 1985 Feb;3(2):139-44. doi: 10.1016/s0167-8140(85)80018-9.
4
Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer.
Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):587-91. doi: 10.1016/0360-3016(86)90067-2.
5
The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
Radiother Oncol. 1995 May;35(2):100-6. doi: 10.1016/0167-8140(95)01539-s.
6
The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1649-55. doi: 10.1016/0360-3016(82)90282-6.
7
[SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].同步放化疗联合顺铂治疗局部晚期头颈部鳞状细胞癌(SCHNC)。早期结果及毒性评估
Otolaryngol Pol. 2011 Sep;65(5 Suppl):117-25. doi: 10.1016/S0030-6657(11)70719-3.
8
Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.晚期头颈癌加速分割放疗方案两种变体的随机I/II期试验:RTOG 88-09的结果
Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):589-97. doi: 10.1016/0360-3016(95)00078-D.
9
Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.米索硝唑增敏放疗对头颈部 III-IV 期鳞状细胞癌患者的预后无显著影响。
Int J Radiat Oncol Biol Phys. 1987 Aug;13(8):1155-60. doi: 10.1016/0360-3016(87)90188-x.
10
Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer.晚期头颈癌加速超分割放疗的疗效改善
Int J Cancer. 2000 Apr 20;90(2):80-91.

引用本文的文献

1
The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma.咪唑或醌类化合物作为放射增敏剂与放射疗法联合治疗头颈部鳞状细胞癌的治疗潜力
Cancers (Basel). 2022 Sep 27;14(19):4694. doi: 10.3390/cancers14194694.
2
Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma.克服缺氧对头颈部鳞状细胞癌放疗抗性的影响
Cancers (Basel). 2022 Aug 26;14(17):4130. doi: 10.3390/cancers14174130.
3
Altered fractionation radiotherapy with or without chemotherapy in the treatment of head and neck cancer: a network meta-analysis.
头颈部癌治疗中采用或不采用化疗的分割放疗改变:一项网状荟萃分析
Onco Targets Ther. 2018 Sep 4;11:5465-5483. doi: 10.2147/OTT.S172018. eCollection 2018.
4
Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.在局部晚期头颈部癌中进行放化疗联合或不联合替拉扎胺的 III 期临床试验中,血浆 HGF 和 IL-8 的预后和预测意义。
Clin Cancer Res. 2012 Mar 15;18(6):1798-807. doi: 10.1158/1078-0432.CCR-11-2094. Epub 2012 Mar 1.
5
Clinical biomarkers for hypoxia targeting.用于靶向缺氧的临床生物标志物。
Cancer Metastasis Rev. 2008 Sep;27(3):351-62. doi: 10.1007/s10555-008-9144-9.
6
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.头颈部未切除局部晚期鳞状细胞癌超分割与加速放疗及放化疗联合方案的荟萃分析
BMC Cancer. 2006 Jan 31;6:28. doi: 10.1186/1471-2407-6-28.
7
Altered fractionation in the treatment of head and neck cancer.头颈部癌治疗中分割方式的改变。
Curr Oncol Rep. 1999;1(2):110-23. doi: 10.1007/s11912-999-0021-7.